A scientific technique that rapidly increases the body's production of anti-inflammatory cells promoted healing from heart attacks in mice, according to a new study by investigators from the Smidt Heart Institute at Cedars-Sinai. Once adapted to treat humans, the technique could potentially be used to repair heart muscle damage after a heart attack and be applied to a variety of inflammatory disorders.

The investigators' findings were published in the peer-reviewed Journal of Clinical Investigation.

Scientists have long struggled to target proteins that lack defined structure and are involved in cancer, neurodegenerative disorders like Parkinson's disease, and other serious illnesses. Now, a new study from Scripps Research demonstrates a proof of concept for a new strategy: engineering proteases - enzymes that cut proteins at specific sites - to selectively degrade these elusive targets with high precision in the proteome of human cells.

Among other functions, the NK cells (Natural Killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot overcome the tumour’s defense mechanism and the cancer grows. Now, a study published in Nature Immunology, with the involvement of the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University, proposes a new approach to strengthen NK cells in their fight agaist tumour cells.

Scientists from Johns Hopkins Medicine and eight other institutions in the United States, Africa and Europe say they have identified a potential new gene target that could be edited to treat sickle cell disease, an inherited blood disorder marked by sickle-shaped red blood cells that cause intense pain and shorten lifespans.

The potential target, the FLT1 gene, contributes to the production of a protein, fetal hemoglobin, whose presence is already known to improve the lifespan of people with sickle cell disease.

Physical fitness and increasing muscle strength could reduce the mortality rate for cancer patients by between 31% to 46%, new research from Edith Cowan University (ECU) has found.

Around 20 million new cancer cases were reported in 2022, with 9.7 million cancer deaths reported world-wide during the same period, with experts expecting the trend to increase in the coming decades.

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalisation if they stop taking heart failure medications. This is according to a new study from Karolinska Institutet published in the top-ranked journal Circulation.

"Our finding raises awareness about the importance of implementing and not withdrawing medical treatments in daily clinical practice even if patients with heart failure experience an improvement in symptoms and pump function," says the study's last author Gianluigi Savarese,

A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered - which could help drug delivery in cancer treatment.

In a paper published in PNAS, researchers at King's College London and the University of Washington describe the unique 3D structure of this protein, which is now being used to develop cancer drug delivery systems that can target drugs to tumour sites.